Episode Details
Back to Episodes
PRESERFLO vs Trabeculectomy: A New Randomized Trial Tests Which Glaucoma Surgery Really Lowers Pressure Better
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/preserflo-vs-trabeculectomy-a-new-randomized-trial-tests-which-glaucoma-surgery-really-lowers-pressure-better
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
PRESERFLO vs Trabeculectomy: A New Randomized Trial Tests Which Glaucoma Surgery Really Lowers Pressure Better The new trial reports an important change over time: PRESERFLO had lower pressure early after surgery, while trabeculectomy achieved lower pressure at 3 and 12 months. But the published abstract does not provide the exact pressure values or confidence intervals needed to calculate the size of that difference. Here is what the study does—and does not—establish. The short answer The new trial supports trabeculectomy as the stronger pressure-lowering choice when the main goal is a very low pressure. It does not show how many millimeters of mercury a patient gives up by choosing PRESERFLO, because its abstract does not provide the arm-by-arm pressure readings needed to calculate that difference. Across earlier comparative evidence, the average long-term pressure advantage for trabeculectomy has generally been about 1 to 3 mmHg. That difference may matter more when glaucoma is advanced and the target is in the low teens—or lower. PRESERFLO remains a reasonable option for some people whose target is less stringent and who value its design and potential reduction in certain postoperative risks. But it is still bleb-forming filtration surgery: it is not free of scarring, needling, follow-up, or late infection risk. The new trial was published on September 19, 2026, just five days before this article’s date, September 24, 2026. It is an accepted, early online article that may receive final editorial changes. It randomized 99 people: 51 to PRESERFLO MicroShunt with mitomycin C and 48 to trabeculectomy with mitomycin C. The abstract reports lower early pressure with PRESERFLO and lower pressure with trabeculectomy at 3 and 12 months. () What the new randomized trial did Who was studied—and what we can verify The study included adults with primary open-angle glaucoma (POAG) or pseudoexfoliation glaucoma (PEXG) whose disease was progressing despite maximum tolerated treatment. Eligibility required worsening visual-field results and pressure remaining above the patient’s target despite topical and oral medicines. The study was conducted at one center in Poland, with recruitment from April 2023 to October 2024 and 12 months of follow-up. () Some details requested by patients—including the exact numbers of POAG versus PEXG participants, the distribution of glaucoma severity, mean baseline pressure, average number of baseline medications, and the numerical target pressure—are not included in the searchable abstract and methods text available for this review. The full paper may contain additional figures or tables, but those values are not reproduced here rather than guessed. The study says that disease progression was assessed with visual fields, but that alone does not establish how many participants had mild, moderate, or advanced damage. () How surgery and randomization were handled The researchers used folded allocation slips to assign patients in a 1:1 ratio immediately before surgery. The slips were prepared by an investigator who did not enroll participants. There was no blocking or stratification, and neither surgeons nor participants could be blinded; outcome assessors were not formally blinded either. The study was registered after rec